ADMA Biologics, Inc. (ADMA)

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Founded in 2004 and headquartered in Ramsey, New Jersey, the company is known for its commitment to delivering innovative immune globulin products. ADMA Biologics is particularly recognized for its product portfolio aimed at addressing unmet medical needs in patients with compromised immune systems. As of the latest available update, Adam Grossman serves as the President and CEO. The company strives to enhance patient health and safety while contributing to advancements in immunotherapy.